Literature DB >> 3992514

Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control.

E A Loeliger, A M van den Besselaar, S M Lewis.   

Abstract

In 1983, the World Health Organization (WHO) published recommendations for normalization, in oral anticoagulant control, of the prothrombin time (PT). The common denominator is the International Sensitivity Index (ISI) of a thromboplastin, obtained by means of thromboplastin calibration. The common scale is that of the International Normalized Ratio (INR). The INR is the PT ratio (Formula: see text) which would have been found with the WHO primary international reference preparation (IRP) 67/40. The reliability of the INR depends on the extent of calibration precision, patient-specific influences, as well as inter-laboratory variation in the PT determination. Under well-controlled conditions the overall coefficient of variation (CV) of the INR is 11-13.5%, if thromboplastins of ISI congruent to 1 are used. For so-called low-sensitivity thromboplastins (ISI congruent to 2-2.5), the overall variation is larger due to a large between-laboratory variation of the measured PT-ratios. The user of thromboplastin will be provided with a chart or graph enabling him to convert the conventional terms used for expressing PTs into INRs. For quality assurance, and to prepare his own calibration chart if necessary, he should check normalization by means of control plasmas to which INRs have been assigned. There is sufficient clinical evidence to express optimal therapeutic ranges in terms of INR. Manufacturers should revise and adapt their inserts where necessary in order to conform to these requirements.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992514

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  ISI value of thromboplastin.

Authors:  A M Van den Besselaar
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.

Authors:  S Kitchen; F E Preston
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

Review 3.  Accuracy, precision, and quality control for point-of-care testing of oral anticoagulation.

Authors:  A M van den Besselaar
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

4.  [Risk factors of a new cardio-embolic cerebral accident in non-valvular atrial fibrillation treated with acenocoumarol].

Authors:  E Vázquez Muñoz; J Gómez Cerezo; A Fernández Pavón
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

Review 5.  Therapeutic target values in oral anticoagulation--justification of Dutch policy and a warning against the so-called moderate-intensity regimens.

Authors:  E A Loeliger
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'.

Authors: 
Journal:  Eur Heart J       Date:  2010-06-07       Impact factor: 29.983

Review 8.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Authors:  Khaled Abduljalil; Simone Lazar; Michael Natanzon; Weidong Wu; Gregor Zadoyan; Benedict Steffens; Victoria Kohl; Klaus Mörike; Dorota Tomalik-Scharte; Julia Stingl; Matthias Schwab; Job Harenberg; Christoph Gleiter; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

Review 10.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.